Current and historical daily PE Ratio for Bristol-Myers Squibb Co (
) from 1990 to May 17 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Bristol-Myers Squibb stock (FRA:BRM) PE ratio as of May 17 2024 is 0.
More Details
Bristol-Myers Squibb Co (FRA:BRM) PE Ratio (TTM) Chart
Bristol-Myers Squibb Co (FRA:BRM) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1240
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Bristol-Myers Squibb PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-17 | At Loss | 2024-03-12 | 13.9 |
| 2024-05-16 | At Loss | 2024-03-11 | 13.9 |
| 2024-05-15 | At Loss | 2024-03-08 | 13.7 |
| 2024-05-14 | At Loss | 2024-03-07 | 13.7 |
| 2024-05-13 | At Loss | 2024-03-06 | 13.7 |
| 2024-05-10 | At Loss | 2024-03-05 | 13.1 |
| 2024-05-09 | At Loss | 2024-03-04 | 13.0 |
| 2024-05-08 | At Loss | 2024-03-01 | 13.1 |
| 2024-05-07 | At Loss | 2024-02-29 | 13.1 |
| 2024-05-06 | At Loss | 2024-02-28 | 13.0 |
| 2024-05-03 | At Loss | 2024-02-27 | 13.0 |
| 2024-05-02 | At Loss | 2024-02-26 | 13.2 |
| 2024-04-30 | At Loss | 2024-02-23 | 13.4 |
| 2024-04-29 | At Loss | 2024-02-22 | 13.1 |
| 2024-04-26 | At Loss | 2024-02-21 | 13.0 |
| 2024-04-25 | At Loss | 2024-02-20 | 13.0 |
| 2024-04-24 | At Loss | 2024-02-19 | 12.9 |
| 2024-04-23 | At Loss | 2024-02-16 | 12.8 |
| 2024-04-22 | At Loss | 2024-02-15 | 12.8 |
| 2024-04-19 | At Loss | 2024-02-14 | 12.8 |
| 2024-04-18 | At Loss | 2024-02-13 | 12.6 |
| 2024-04-17 | At Loss | 2024-02-12 | 12.9 |
| 2024-04-16 | At Loss | 2024-02-09 | 12.8 |
| 2024-04-15 | At Loss | 2024-02-08 | 12.5 |
| 2024-04-12 | At Loss | 2024-02-07 | 12.6 |
| 2024-04-11 | At Loss | 2024-02-06 | 13.0 |
| 2024-04-10 | At Loss | 2024-02-05 | 12.4 |
| 2024-04-09 | At Loss | 2024-02-02 | 12.7 |
| 2024-04-08 | At Loss | 2024-02-01 | 12.5 |
| 2024-04-05 | At Loss | 2024-01-31 | 12.8 |
| 2024-04-04 | At Loss | 2024-01-30 | 12.8 |
| 2024-04-03 | At Loss | 2024-01-29 | 12.8 |
| 2024-04-02 | At Loss | 2024-01-26 | 12.8 |
| 2024-03-28 | At Loss | 2024-01-25 | 12.9 |
| 2024-03-27 | 13.7 | 2024-01-24 | 13.0 |
| 2024-03-26 | 13.6 | 2024-01-23 | 12.8 |
| 2024-03-25 | 13.5 | 2024-01-22 | 12.8 |
| 2024-03-22 | 13.5 | 2024-01-19 | 12.9 |
| 2024-03-21 | 13.3 | 2024-01-18 | 12.6 |
| 2024-03-20 | 13.4 | 2024-01-17 | 12.7 |
| 2024-03-19 | 13.3 | 2024-01-16 | 12.8 |
| 2024-03-18 | 13.4 | 2024-01-12 | 12.8 |
| 2024-03-15 | 13.3 | 2024-01-11 | 12.8 |
| 2024-03-14 | 13.4 | 2024-01-10 | 12.9 |
| 2024-03-13 | 13.6 | 2024-01-09 | 13.2 |
Bristol-Myers Squibb Co (FRA:BRM) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
ISIN : US1101221083
Share Class Description:
FRA:BRM: Ordinary SharesCompare
Compare
Traded in other countries / regions
BMY.USA0R1F.UKBMY.MexicoBRM.GermanyBMY.ArgentinaBMY.PeruBMYB34.Brazil1BMY.ItalyBMYS.AustriaBMY.Switzerland IPO Date
1952-06-23Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers